Early Identification of Pathologic Complete Response to Neoadjuvant Chemotherapy Using Multiphase DCE‐MRI by Siamese Network in Breast Cancer: A Longitudinal Multicenter Study
Authors:
- 18 December 2023
- journal article
- research article
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 60 (4) , 1325-1337
Abstract
Background: Siamese network (SN) using longitudinal DCE‐MRI for pathologic complete response (pCR) identification lack a unified approach to phases selection.Purpose: To identify pCR in early‐stage NAC, using SN with longitudinal DCE‐MRI and introducing IPS for phases selection.Study Type: Multicenter, longitudinal.Population: Center A: 162 female patients (50.63 ± 8.41 years) divided 7:3 into training and internal validation cohorts. Center B: 61 female patients (50.08 ± 7.82 years) were used as an external validation cohort.Field Strength/Sequence: Center A: single vendor 3.0 T with a compressed‐sensing volume interpolated breath‐hold examination sequence. Center B: single vendor 1.5 T with volume interpolated breath‐hold examination sequence.Assessment: Patients underwent DCE‐MRI before and after two NAC cycles, with tumor regions of interest (ROI) manually delineated. Histopathology was the reference for pCR identification. Models developed included a clinical one, four SN models based on IPS‐selected phases, and integrated models combining clinical and SN features.Statistical Tests: Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). The DeLong test was used to compare AUCs. Net reclassification improvement and integrated discrimination improvement (IDI) tests were employed for performance comparison. P < 0.05 was considered significant.Results: In internal and external validation cohorts, the clinical model showed AUCs of 0.760 and 0.718. SN and integrated models, with increasing phases via IPS, achieved AUCs ranging from 0.813 to 0.951 and 0.818 to 0.922. Notably, SN‐3 and integrated‐3 and integrated‐4 outperformed the clinical model. However, input phases beyond 20% did not significantly enhance performance (IDI test: SN‐4 vs. SN‐3, P = 0.314 and 0.630; integrated‐4 vs. integrated‐3, P = 0.785 and 0.709).Data Conclusion: The longitudinal multiphase DCE‐MRI based on the SN demonstrates promise for identifying pCR in breast cancer.Evidence Level: 1Technical Efficacy: Stage 4Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (2023CDJYGRH‐YB04)
- Natural Science Foundation of Chongqing Municipality (CSTB2022NSCQ‐MSX1158, CSTB2023NSCQ‐MSX0787)
This publication has 33 references indexed in Scilit:
- Radiomics of Multiparametric MRI for Pretreatment Prediction of Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Multicenter StudyClinical Cancer Research, 2019
- Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy forHER2 (ERBB2)–Positive Breast CancerJAMA Network Open, 2019
- Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast CancerNeoplasia, 2019
- Patient-Friendly Summary of the ACR Appropriateness Criteria: Monitoring Response to Neoadjuvant Systemic Therapy for Breast CancerJournal of the American College of Radiology, 2018
- Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancerAnnals of Oncology, 2017
- Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRIBreast Cancer Research, 2017
- Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free SurvivalRadiology, 2016
- Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-upBreast Cancer Research and Treatment, 2016
- Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicatorsEuropean Radiology, 2014
- Response-Guided Neoadjuvant Chemotherapy for Breast CancerJournal of Clinical Oncology, 2013